The IASLC - Lancet Commission on Lung Cancer
The IASLC - Lancet Commission on Lung Cancer

The IASLC - Lancet Commission
on Lung Cancer

Reimagining the Future of Lung Cancer Care: Equitable, Innovative, Global.

The IASLC - Lancet Commission unites global experts, policymakers, and patients to transform lung cancer prevention, diagnosis, and treatment.

Get Involved

The Commission

Reimagining the Future of Lung Cancer Control

The IASLC–Lancet Commission on Lung Cancer brings together leading clinicians, researchers, policymakers, and patient advocates from across the globe to address one of the world’s most pressing health challenges. Lung cancer remains the leading cause of cancer mortality worldwide, yet inequities in prevention, diagnosis, treatment, and research continue to persist.

Our Vision

A future where lung cancer prevention, care, and research are equitable, innovative, and globally impactful - ensuring that progress benefits every individual, everywhere.

Highlights

Announcement
  • The Lancet Commission on Lung Cancer established to drive global change
Launch Event Read the Lancet Comment

Objectives of The IASLC - Lancet Commission

This landmark Commission aims to:

  • Reframe the global lung cancer agenda
    by adopting an innovative, forward-looking, and equity-driven approach.
  • Generate evidence-based recommendations
    that highlight opportunities to prevent, detect, and treat lung cancer more effectively.
  • Promote equitable, affordable access
    to cutting-edge therapies, diagnostics, and technologies across diverse healthcare settings.
  • Strengthen collaboration
    between governments, health systems, and civil society to improve outcomes for all patients, irrespective of geography or income.

Through rigorous analysis and global consultation, the Commission will identify pathways to:

  • Reduce the global burden of lung cancer through prevention and early detection.
  • Improve affordability and accessibility of novel treatments.
  • Address stigma and disparities in care.
  • Align research priorities with real-world patient needs.
  • Invest in training, retention and support of the lung cancer workforce.

Why This Matters

Lung cancer remains the leading cause of cancer-related death worldwide,
responsible for more than 1.8 million deaths annually.

Despite advances in science and technology, lung cancer outcomes remain deeply unequal. Low- and middle-income countries shoulder the majority of the burden yet have the least access to innovations. The IASLC–Lancet Commission is uniquely positioned to catalyze change by uniting scientific evidence with policy action, and by placing patients at the centre of every recommendation. With the right strategies, research, and policy action, we can transform outcomes for millions of patients and families.

Get Involved